Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iVAC-CLL01: Individualized Peptide Vaccine in CLL
NCT02802943Phase 2Completed
- Sponsor
- University Hospital Tübingen
- Start
- Oct 2016
- Primary completion
- Sep 2022
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of CLL-VAC in chronic lymphocytic leukemia (CLL), sponsored by University Hospital Tübingen. Primary endpoint: Induction of peptide-specific T cell responses at 6 months. Started Oct 2016; status: completed.
02
Drugs
CLL-VAC
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02802943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02802943.